000 06191cam a2200769 i 4500
005 20250919004731.0
008 150728s2015 enka ob 001 0 eng
020 _a9781118892565
_cRM479.60
020 _a1118892569 (ePub)
020 _a9781118892558 (Adobe PDF)
020 _a1118892550 (Adobe PDF)
020 _z9781118892541 (cloth)
020 _a9781118892572
020 _a1118892577
020 _a1118892542 (cloth)
020 _a9781118892541 (cloth)
039 9 _a201511061110
_bzainol
_c201508041459
_dfashihah
_y07-28-2015
_zfashihah
040 _aQV269
_b.L474a 2015 9
090 _aQV269.L474a 2015 9
100 1 _aLednicer, Daniel,
_d1929-
_eauthor
245 1 0 _aAntineoplastic drugs :
_borganic syntheses /
_cDaniel Lednicer.
264 1 _aChichester, West Sussex :
_bJohn Wiley & Sons. Ltd,
_c2015.
300 _a1 online resource.
300 _axiv, 213 pages :
_billustration ;
_c25 cm.
336 _atext
_2rdacontent
337 _acomputer
_2rdamedia
337 _aunmediated
_2rdamedia
338 _aonline resource
_2rdacarrier
338 _avolume
_2rdacarrier
504 _aIncludes bibliographical references and index.
505 0 _aTitle Page; Copyright Page; Contents; Preface; Introduction; Chapter 1 Alkylating Agents; 1.1 bis-Chloroethyl Amines; 1.2 Several Other Chloroethyl Agents; 1.3 Platinum-Based Antineoplastic Agents; 1.4 Miscellaneous Alkylating Agents; References; Chapter 2 Antimetabolites; 2.1 Introduction; 2.2 Folate Antagonists; 2.2.1 Compounds with Glutamate Side Chain; 2.2.2 Compounds Lacking the Glutamate Moiety; 2.2.3 Methoxylated Benzenes; 2.3 Pyrimidines and Purines; 2.3.1 Aglycones; 2.3.2 Saccharide-Linked Compounds; References; Chapter 3 Hormone Blocking Anticancer Drugs; 3.1 Introduction
505 8 _a3.2 Estrogen Antagonists3.2.1 Estrogen Antagonists; 3.2.2 Aromatase Inhibitors; 3.3 Androgen Antagonists; 3.3.1 Non-steroidal Antian drogens; 3.3.2 Steroid Androgen Antagonists; References; Chapter 4 Topoisomerase Inhibitors; 4.1 Introduction; 4.2 Anthracyclines; 4.3 Anthraquinones and Anthrapyrazoles; 4.3.1 Anthraquinones with Two Aminoalkyl Side Chains; 4.3.2 Anthraquinones with a Fused Pyrazole Ring; 4.3.3 Heterocyclic Anthraquinones; 4.4 Camptothecins; 4.4.1 Compounds from Modified Camptothecin; 4.4.2 Camptothecins by Total Synthesis; 4.5 Miscellaneous Topoisomerase Inhibitors; References
505 8 _aChapter 5 Mitotic Inhibitors5.1 Introduction; 5.2 Taxanes; 5.3 Wholly Synthetic Compounds; 5.3.1 Carbocyclic Compounds; 5.3.2 Peptide-Like Inhibitors; 5.3.3 Monocyclic Heterocyclic Inhibitors; 5.3.4 Bicyclic 5:6 Heterocyclic Inhibitors; 5.3.5 Bicyclic 6:6 Heterocyclic Tubulin Inhibitors; References; Chapter 6 Matrix Metalloproteinase Inhibitors; 6.1 Introduction; 6.2 Hydroxamates; 6.2.1 Agents with an Isobutyl Moiety; 6.2.2 A Thiomorpholine; 6.2.3 Sulfamates; 6.2.4 Miscellaneous Compounds; References; Chapter 7 Histone Deacetylase Inhibitors; 7.1 Introduction; 7.2 Hydroxamates
505 8 _a7.3 PhenylenediaminesReferences; Chapter 8 Enzyme Inhibitor, Part I, Tyrosine Kinases; 8.1 Introduction; 8.2 Epidermal Growth Factor Inhibitors; 8.3 VEGF; 8.3.1 Fused Ring Compounds; 8.3.2 Linear Arrays; 8.4 SRC Nonreceptor Tyrosine Kinase; 8.5 PDGF; 8.6 EGF; 8.7 Other TKI; 8.7.1 Linear Arrays; 8.7.2 Compounds with Two Fused Rings; 8.8 Janus Kinase Inhibitors; References; Chapter 9 Enzyme Inhibitors: Part II Additional Targets; 9.1 Serine-Threonine Kinase Inhibitors; 9.2 Additional Enzyme Inhibitors; 9.2.1 Farnesyl Transferase Inhibitors; 9.2.2 Cyclin-Dependent Kinase Inhibitors
505 8 _a9.2.3 Proteasome Inhibitors9.2.4 PARP Inhibitors; 9.2.5 Various Other Enzyme Inhibitors; References; Chapter 10 Miscellaneous Antineoplastic Agents; 10.1 Acyclic; 10.2 Monocyclic; 10.3 Two Linked Rings; 10.4 Rings on a Chain; 10.4.1 Two Rings; 10.4.2 Four and More Rings; 10.5 Fused Rings; 10.5.1 Indoles; 10.5.2 Purine-Like; 10.5.3 Tetralins and a Naphthalene; 10.5.4 Etc.; References; Appendix A; Index of Heterocycle Syntheses; Subject Index; EULA
520 _a'Antineoplastic Drugs: Organic Syntheses is written to appeal to organic and medicinal chemists in industry and academia. It is beneficial to those composing grant proposals for NCI and related organizations'--
_cProvided by publisher.
588 _aDescription based on print version record and CIP data provided by publisher.
650 2 _aAntineoplastic agents.
650 2 _aDrugs
_xSynthesis.
650 7 _aSCIENCE / Life Sciences / Biochemistry.
_2bisacsh
650 4 _aAntimetabolites.
650 4 _aAntineoplastic agents.
650 4 _aCancer.
650 4 _aDrugs -- Administration.
650 4 _aPharmacognosy.
650 7 _aAntineoplastic agents.
_2fast
_0(OCoLC)fst00810595
650 7 _aDrugs
_xSynthesis.
_2fast
_0(OCoLC)fst00898936
655 4 _aElectronic books.
655 7 _aElectronic books.
_2local
655 0 _aElectronic books.
776 0 8 _iPrint version:
_aLednicer, Daniel, 1929-
_tAntineoplastic drugs
_dChichester, West Sussex : Wiley, 2015
_z9781118892541
_w(DLC) 2015008084
856 4 0 _3Cover image
_uhttp://catalogimages.wiley.com/images/db/jimages/9781118892541.jpg
856 4 0 _3EBSCOhost
_uhttp://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=966490
856 4 0 _3John Wiley
_uhttp://dx.doi.org/10.1002/9781118892572
856 4 0 _uhttp://lib.myilibrary.com?id=770051
_zConnect to MyiLibrary resource.
856 4 0 _uhttp://alltitles.ebrary.com/Doc?id=11032414
_zAn electronic book accessible through the World Wide Web; click to view
_3ebrary
856 4 0 _zClick here to view book
_uhttp://public.eblib.com/choice/PublicFullRecord.aspx?p=1964101
_3Ebook Library
856 4 0 _uhttp://rbdigital.oneclickdigital.com
907 _a.b16184439
_b2019-11-12
_c2019-11-12
942 _c01
_n0
_kQV269.L474a 2015 9
914 _avtls003590747
990 _azr
991 _aProgram Sains Bioperubatan, Pusat Pengajian Sains Diagnostik dan Kesihatan Gunaan, FSK, KKL
998 _ad
_b2015-02-07
_cm
_da
_feng
_genk
_y0
_z.b16184439
999 _c596241
_d596241